Design Therapeutics, Inc.
For the period ended Nov 4, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 4, 2026 · Filed Nov 4, 2026
Use the contents to explore the available documents and sections.
DSGN$10.21+5.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except share and per share data)
(in thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| (unaudited) | ||||
| Operating expenses: | ||||
| Research and development | $16,926 | $14,589 | $47,693 | $45,704 |
| General and administrative | 5,304 | 4,722 | 16,420 | 15,594 |
| Total operating expenses | 22,230 | 19,311 | 64,113 | 61,298 |
| Loss from operations | (22,230) | (19,311) | (64,113) | (61,298) |
| Other income, net | 1,942 | 2,314 | 6,024 | 7,503 |
| Net loss | $(20,288) | $(16,997) | $(58,089) | $(53,795) |
| Net loss per share, basic and diluted | $(0.32) | $(0.30) | $(0.93) | $(0.95) |
| Weighted-average shares of common stock outstanding, basic and diluted | 63,035,529 | 56,950,999 | 62,330,974 | 56,856,779 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.